Skip to main content
. 2015 Dec 28;7(4):4414–4427. doi: 10.18632/oncotarget.6780

Figure 6. GNA13 downregulates FOXO1 transcriptional activity via activation of the PI3K/AKT and MAPK/ERK signaling pathway.

Figure 6

(A and B) Related FOXO1 reporter activity (A) and c-Myc reporter activity (B) in GNA13-transduced cells or GNA13 shRNA–infected cells. (C), Western blot analysis of p-AKT, total AKT, p-ERK, total ERK, c-Myc, p-GSK-3β, total GSK-3β, p-FOXO1, and total FOXO1 in GNA13-transduced cells or GNA13 shRNA–infected cells. (D) AGS/GNA13 and HGC-27/GNA13 cells were treated with the AKT inhibitor LY294002 (20 lM), the ERK kinase inhibitor U0126 (20 lM) or DMSO for 24 h, then harvested to examine the expression levels of the indicated proteins by Western blotting. (E, F and G) AGS/GNA13 and HGC-27/GNA13 proliferation and tumorigenicity were determined by MTT (E), colony formation assays (F) and anchorage-independent growth assay (G) after treatment with LY294002, U0126 or DMSO. *P < 0.05; **P < 0.01.